Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer

Thoracic Cancer
Yingying PanCaicun Zhou

Abstract

The impact of primary tumor size on the therapeutic outcomes of EGFR-tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC) with EGFR mutation remains unclear. A total of 291 consecutive patients with advanced EGFR-mutant NSCLC administered first-line EGFR-TKIs were enrolled. Computed tomography was used to assess primary tumor diameter. The amplification refractory mutation system plus was used to quantitatively evaluate the abundance of EGFR mutations. Associations between depth of response, abundance of EGFR mutations, and tumor size was investigated. Patients were divided into three groups according to T classification: ≤ 3 cm (n = 109), 3-5 cm (n = 121), and > 5 cm (n = 61). Median progression-free survival (PFS) was significantly longer in the ≤ 3 cm and 3-5 cm groups compared to the > 5 cm group (10.8 vs. 10.5 vs. 7.1 months; P < 0.001). Subgroup analysis revealed a consistent result in patients with exon 19 deletion and 21 L858R mutation. Multivariate analysis revealed that tumor size was an independent predictive factor for PFS (hazard ratio 1.528, 95% confidence interval 1.104-2.115; P = 0.010). Larger tumors (> 5 cm) were marginally significantly less EGFR-mutant abundant than smaller tumors...Continue Reading

References

Sep 27, 2007·Journal of the National Cancer Institute·Olivier TrédanIan F Tannock
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jan 22, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·William D TravisDavid Yankelewitz
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Sep 18, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Daniel MorgenszternRamaswamy Govindan
Aug 15, 2013·British Journal of Cancer·D E GerberD H Johnson
Apr 2, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Wei LiGerald Schmid-Bindert
Apr 25, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·William D TravisUNKNOWN International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and Advisory Board Members
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matteo CanalePaola Ulivi
Mar 14, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Paul A VanderLaanDaniel B Costa
Apr 5, 2017·Journal of the National Cancer Institute·Imane ChaibRafael Rosell
Jun 19, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Xuefei LiFred R Hirsch
Feb 8, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Fei ZhouCaicun Zhou
Mar 28, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Chee Khoon LeeJames Chih-Hsin Yang
Jun 1, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Qinghua XuCaicun Zhou
Aug 16, 2018·Cancer Medicine·Shuai LiangMengzhao Wang

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

SPSS
ARMS
GraphPad Prism

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.